What Are the Requirements for Risk Management Documents for Medical Device Registration in Japan?

Answer: For the question "What are the requirements for risk management documents for medical device registration in Japan?", companies should first confirm the target country, product risk class, applicable regulatory pathway, and existing documentation base. Then assess technical files, quality system, labels and instructions for use (IFU), local agent, clinical evidence, and post-market maintenance requirements. AIMEILI recommends conducting a documentation gap assessment before formal submission to avoid prolonged project timelines due to unclear classification, documentation, or authorization arrangements.

Applicable Scenarios and Core Questions

Companies searching for "What are the requirements for risk management documents for medical device registration in Japan?" are typically not seeking conceptual explanations. Instead, they want to determine whether their existing documentation can support a submission in the target market, whether a local agent or authorized representative is needed, why timelines may be extended, and which issues could affect their launch plans. This question often involves product classification, registration pathways, evidence chains, label localization, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America simultaneously, answering the process for a single country is insufficient. A more valuable approach is to first develop reusable versions of core technical files, quality system certificates, performance verification, clinical evidence, and labels/IFU, and then localize them according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the product's intended use, mechanism of action, use scenario, body contact method, duration of use, whether it is sterile, whether it is active, and whether it includes software or IVD attributes. Then determine the risk class and submission pathway. If the pathway is incorrectly identified, subsequent translation, notarization, authorization, testing, and supplementary documentation will all deviate from the correct direction.

For target market projects, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles import and post-market events, who triggers changes, and who maintains renewal documentation. If these issues are only vaguely addressed in commercial contracts, they can easily affect market control later.

Documentation and Evidence

Common documents include product description, model/specification matrix, intended use, risk classification rationale, ISO 13485 or applicable quality system certification, technical files, performance verification reports, risk management documents, clinical evaluation or clinical evidence, labels and IFU, authorization documents, existing registration certificates, manufacturer's declarations, and post-market surveillance documentation.

The key to documentation quality is not quantity but consistency. IFU claims, test report coverage of models, clinical evidence applicability, risk management conclusions, label warnings, and registration application form information must support each other. Regulatory authorities focus on whether the product is safe, effective, and traceable for its intended use, not on how many documents the company has uploaded.

Common Mistakes

The most common problem is treating the registration project as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Submitting directly translated NMPA documents without restructuring evidence according to the target market pathway.
• Too many model specifications but insufficient coverage by test reports, clinical evidence, or labels.
• Selecting a local agent solely based on sales cooperation without clarifying regulatory responsibilities, certificate control, and post-market maintenance duties.
• Inconsistencies among labels, IFU, promotional materials, and registration claims, leading to deficiency letters or post-market compliance risks.
• Failing to plan for multi-country document reuse in advance, resulting in repeated preparation for each country and amplified costs and timelines.

Company Preparation Checklist

Before starting a project, companies should use an internal checklist to confirm their documentation base to avoid discovering critical evidence gaps after submission.

• Compile a target product list, model/specification matrix, and intended use statements.
• Verify whether existing NMPA, CE, FDA, or other market registration documents can be reused.
• Prepare ISO 13485 certificates, test reports, risk management, clinical evaluation, and English IFU.
• Confirm the responsibilities, fees, certificate control, and exit mechanisms of local agents or authorized representatives.
• Establish a target country gap assessment table specifying what needs additional testing, translation, notarization, or supplementary declarations.

AIMEILI Perspective

AIMEILI recommends that companies not view target market registration as a one-time document submission but manage it as an overseas market access engineering project. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first, then converting according to national requirements, is usually faster, more stable, and more conducive to subsequent changes and renewals than preparing documents on a country-by-country ad hoc basis.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, consistency of the documentation evidence chain; third, the regulatory responsibility boundaries of local partners. If these three are unclear, even if the documentation appears extensive, the project may still face repeated issues during deficiency responses, agent communication, and post-market maintenance.

Frequently Asked Follow-up Questions

Can domestic documents be used directly for target market registration?

Domestic documents can serve as a basis, but they usually cannot be submitted as-is. Companies need to adjust the document structure, language, labels, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments, and agent selection in advance.

Why does the choice of local agent affect registration quality?

Local agents typically participate in registration communication, changes, renewals, and post-market event handling. Unclear responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing such registration projects, companies should establish a project ledger that manages the product list, model specifications, registration pathway, document owners, translation status, testing status, local agent communication records, and expected submission dates in a single table. This allows for timely identification of documentation gaps and helps management assess whether the project will affect launch plans.

For companies with existing registrations in multiple countries, an evidence reuse matrix should also be established to clarify which documents can serve as core evidence and which must be reissued or supplemented according to national requirements. In particular, labels/IFU, clinical evaluation, risk management, performance verification, and quality system certificates must remain version-consistent.

• Confirm target markets and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify local agent and certificate control.
• Track translation, notarization, testing, and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documents are not isolated certificates. Regulatory authorities typically check consistency among manufacturer name, manufacturing address, product scope, certificate validity, applicable standards, and technical files. If the ISO 13485 certificate scope does not match the submitted product, or if the manufacturing address, model specifications, IFU version, and test reports are inconsistent, even a large volume of documents may trigger requests for supplementary explanations.

Companies should establish an evidence consistency checklist before submission, mapping product name, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label/IFU version, and quality system certificates item by item. This may seem basic, but it can significantly reduce the probability of deficiency letters, especially for projects submitted simultaneously in multiple GHWP member states or for multiple product families.

Localization and Agent Responsibilities

Target market registration projects typically involve local agents, authorized representatives, importers, or registration holders. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also for regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, IFU, and authorization documents cannot be simply translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies with existing CE, FDA, NMPA, or other market documents, the focus of localization is to convert reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest significant effort in obtaining certificates but neglect post-market maintenance. As a result, when manufacturing address changes, model expansion, IFU updates, or agent changes occur, the certificate may become disconnected from market sales.

AIMEILI recommends that companies incorporate this issue into annual international registration plan management: first clarify target market priorities, then establish reusable document packages and country gap lists, and finally schedule submission, deficiency response, post-market maintenance, and renewal milestones. The value of this approach is not only improving efficiency for a single country but also enabling companies to build replicable overseas compliance capabilities, reducing the cost of starting from scratch each time they enter a new market.

Continue Reading

Previous: How to Group Multiple Models for Medical Device Registration in Japan?

Next: How to Prepare Performance Verification Documents for Medical Device Registration in Japan?

Recommended Reading:

• How to Choose a Local Agent for Medical Device Registration in Brazil?
• How to Divide Authorized Representative Responsibilities for Medical Device Registration in Brazil?
• Why Do Registration Timelines for Medical Device Registration in Brazil Get Extended?
• Common Reasons for Deficiency Letters in Medical Device Registration in Brazil?
• How to Conduct Post-Market Surveillance for Medical Device Registration in Brazil?
• When to Report Changes for Medical Device Registration in Brazil?

Return to FAQ Center | News | Contact AIMEILI

Content Review and Applicable Boundaries

Author: AIMEILI Regulatory Editorial Team

Professional Review: AIMEILI Medical Device International Registration Project Team

Source Principle: Priority is given to official regulatory authorities, international organizations, standards organizations, and publicly available regulatory information; industry media and project experience are used only as auxiliary judgment.

Applicable Boundaries: This article is intended for preliminary understanding, document preparation, and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions, or legal opinions.

Published: July 15, 2026

Updated: July 15, 2026